

OFFICIALLY LICENSED
BEST OF ASCO[®]
2018 ANNUAL MEETING

15 e 16 de junho de 2018
WTC São Paulo • Events Center
Brasil - São Paulo

CONVIDADOS
ESTRANGEIROS

Caio Rocha Lima (EUA)



Otto Metzger (EUA)



COORDENADORES DE MÓDULO



Aknar Calabrich (BA)



Artur Katz (SP)



Carlos Barros (RS)



Fernando Maluf (SP)



Paulo Hoff (SP)



Sérgio Jobin Azevedo (RS)



Sérgio Simon (SP)



William Nassib William Jr. (SP)

Inscrições:

www.lacog.org.br/event/best-of-asco-2018-anual-meeting/97


REALIZAÇÃO:



APOIO:



cura.



ORGANIZAÇÃO:



PROGRAMAÇÃO CIENTÍFICA

Sexta-feira - 15/06/18



10:30 às 12:30 Reunião dos grupos cooperativos (LACOG, GBECAM, EVA, GBOT, GTG).
Apenas para convidados

13:00 às 14:00 Simpósio Satélite - Roche

14:00 Abertura

14:10 às 15:10 Módulo I – GINECOLÓGICO

Coordenadora: Aknar Calabrich (BA)

14:10 às 14:17 **Abstract: 5500 - Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602**

Palestrante: Andréia Cristina de Melo (RJ)

14:18 às 14:25 **Abstract: 5505 - Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.**

Palestrante: Angélica Nogueira Rodrigues (MG)

14:26 às 14:33 **Abstract: 5506 - Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B- MaNGO OV2B-ENGOT OV17**

Palestrante: Daniela de Freitas (SP)

14:34 às 14:41 **Abstract: 5508 - Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab**

Palestrante: Maria Del Pilar Estevez Diz (SP)

14:42 às 15:10 **Discussão**

15:10 às 16:00 Módulo II – MELANOMA

Coordenador: Sérgio Jobin Azevedo (RS)

15:10 às 15:17 **Abstract: 108 - Epcadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study**

Palestrante: Andréia Cristina de Melo (RJ)

15:18 às 15:25 **Abstract: 9501 - Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node**

Palestrante: Sérgio Jobin Azevedo (RS)

15:25 às 15:32 **Abstract: 9502 - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).**

Palestrante: Rodrigo Guedes (BA)

15:33 às 15:40 **Abstract: 9504 - Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma**

Palestrante: Rodrigo R. Munhoz (SP)

15:40 às 16:00 **Discussão**

16:00 às 16:00 **Coffee Break**

16:30 às 18:00	Módulo III – PULMÃO <i>Coordenador: Artur Katz (SP)</i>
16:30 às 16:40	Abstract: 8507 - Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the Phase 2 TRINITY study. Abstract: 8503 - DREAM: A Phase II study of Durvalumab with first line chemotherapy in Mesothelioma: First Results. <i>Palestrante: Clarissa Mathias (BA)</i>
16:41 às 16:51	Abstract: 8506 - Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Abstract: 9006 - Phase III study comparing bevacizumab plus erlotinib to erlotinib patients with untreated NSCLC harboring activating EGFR mutations. NEJ026. <i>Palestrante: Carolina Kawamura Haddad (SP)</i>
16:52 às 16:59	Abstract: LBA9000 - IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab- Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC. <i>Palestrante: Luiz Henrique de Lima Araújo (RJ)</i>
17:00 às 17:07	Abstract: 9001 - Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study. <i>Palestrante: Mauro Zukin (RJ)</i>
17:08 às 17:15	Abstract: 105 - Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC). <i>Palestrante: Ana Caroline Zimmer Gelatti (RS)</i>
17:16 às 17:23	Abstract: LBA4 - Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. <i>Palestrante: Clarissa Baldotto (RJ)</i>
17:24 às 18:00	Discussão

18:00 às 19:00 **Simpósio Satélite - Novartis**

19:00 **Apresentação dos Embaixadores do CURA**

19:15 **Coquetel de Abertura**

PROGRAMAÇÃO CIENTÍFICA

Sábado - 16/06/18



8:00 às 08:50	Simpósio Satélite – LIBBS
8:50 às 10:00	Módulo V – GENITOURINÁRIO <i>Coordenador: Fernando Maluf (SP)</i>
8:50 às 8:57	Abstract: LBA3 - CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial <i>Palestrante: Oren Smaletz (SP)</i>
8:58 às 9:05	Abstract: 4500 - Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427 <i>Palestrante: Fabio A. B. Schutz (SP)</i>
9:06 às 9:13	Abstract: 5000 - A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial <i>Palestrante: André Poisl Fay (RS)</i>
9:14 às 9:21	Abstract: 5001 - 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial <i>Palestrante: Andrey Soares (SP)</i>
9:22 às 9:29	Abstract: 5003 - Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase II trial <i>Palestrante: Igor Morbeck (DF)</i>
9:30 às 10:00	Discussão
10:00	Coffee Break
10:30	Simpósio Satélite - NOVARTIS
11:30 às 13:00	Módulo VI – MAMA <i>Coordenador: Sérgio Simon (SP)</i> <i>Convidado Internacional: Otto Metzger (EUA)</i>
11:30 às 11:37	Abstract: 104 - Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). <i>Palestrante: José Bines (RJ)</i>
11:38 às 11:45	Abstract: 500 - Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. <i>Palestrante: Rafael Kaliks (SP)</i>
11:46 às 11:53	Abstract: 506 - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. <i>Palestrante: Max Mano (SP)</i>
11:54 às 12:01	Abstract: 1000 - Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. <i>Palestrante: Gustavo Werutsky (RS)</i>
12:02 às 12:09	Abstract: LBA1 - TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score <i>Palestrante: Sérgio Simon (SP)</i>

12:10 às 12:17	<p>Abstract: LBA1006 - Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA- mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.</p> <p><i>Palestrante:</i> Tomas Reinert (RS)</p>
12:18 às 12:25	<p>Abstract: 1007 - AZD5363 plus paclitaxel versus placebo plus paclitaxel à first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.</p> <p><i>Palestrante:</i> Daniela Dornelles Rosa (RS)</p>
12:26 às 13:00	Discussão
13:00 às 14:00	Simpósio Satélite - ASTRAZENECA
14:00 às 15:00	Módulo VII – CABEÇA E PESCOÇO
	<i>Coordenador:</i> William Nassib William Jr (SP)
14:00 às 14:07	<p>Abstract: 6000 - Results of a randomized phase II study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone in locally advanced squamous cell carcinoma of the head and neck</p> <p><i>Palestrante:</i> Augusto Mota (BA)</p>
14:08 às 14:15	<p>Abstract: 6006 - Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP)</p> <p><i>Palestrante:</i> Aline Lauda Freitas Chaves (MG)</p>
14:16 às 14:23	<p>Abstract: 6009 - A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).</p> <p><i>Palestrante:</i> Pedro de Marchi (SP)</p>
14:24 às 14:31	<p>Abstract: 6008 - Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC).</p> <p><i>Palestrante:</i> William Nassib William Jr (SP)</p>
14:32 às 15:00	Discussão
15:00	Módulo VIII – GASTROINTESTINAL + COLORRETAL
	<i>Coordenador:</i> Paulo Hoff (SP)
	<i>Convidado Internacional:</i> Caio Rocha Lima (EUA)
15:00 às 15:07	<p>Abstract: 3501 - Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer</p> <p><i>Palestrante:</i> Rui Weschenfelder (RS)</p>
15:08 às 15:15	<p>Abstract: LBA3503 - A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.</p> <p><i>Palestrante:</i> Fabio Ferreira (SP)</p>
15:16 às 15:23	<p>Abstract: 3505 - First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab à maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study</p> <p><i>Palestrante:</i> Fernanda Capareli (SP)</p>
15:24 às 15:34	<p>Abstract: 3514 - KEYNOTE-164: Pembrolizumab for Patients With Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer.</p> <p>Abstract: 4019 - Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.</p> <p><i>Palestrante:</i> Jorge Sabbaga (SP)</p>
15:35 às 15:42	<p>Abstract: LBA4001 - Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas</p> <p><i>Palestrante:</i> Anelisa Coutinho (BA)</p>

15:43 às 15:50	Abstract: 4004 - A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211) <i>Palestrante: Rachel Riechelman (SP)</i>
15:51 às 15:58	Abstract: LBA4008 - Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. <i>Palestrante: Gabriel Prola (RS)</i>
15:59 às 16:30	Discussão
16:30 às 18:00	Sessão Especial de Encerramento – O que muda na prática <i>Coordenador: Carlos Barrios (RS)</i>
16:30 às 16:45	Mama <i>Palestrante: Otto Metzger (EUA)</i>
16:45 às 17:00	Pulmão <i>Palestrante: William Nassib William Jr (SP)</i>
17:00 às 17:15	GI <i>Palestrante: Caio Rocha Lima (EUA)</i>
17:15 às 17:30	GU <i>Palestrante: Fernando Maluf (SP)</i>
17:30 às 18:00	Outros tumores e Discussão
18:00	Encerramento